Why it matters now
Global trade tensions and geopolitical shifts are leading to an increased use of tariffs as policy tools. The pharmaceutical industry, with its complex and globally interconnected supply chains, is particularly vulnerable. Tariffs can significantly increase the cost of active pharmaceutical ingredients (APIs), excipients, and finished drug products, impacting affordability and availability. Understanding these exposures is critical for maintaining supply chain resilience and business continuity.
Who is exposed
Pharmaceutical supply chains face increased costs for imported raw materials and finished products, impacting profitability. Drug manufacturers may need to re-evaluate sourcing strategies or absorb higher expenses. Distributors could see changes in product availability and pricing. Patients ultimately bear the burden of higher drug costs or potential shortages. Companies with significant international manufacturing footprints are particularly exposed to these policy shifts.
Most relevant for: Chief Procurement Officer, Head of Supply Chain, Government Affairs
What this Viewpoint covers
- Which specific pharmaceutical product categories are most susceptible to current tariffs?
- How do tariffs impact the cost of active pharmaceutical ingredients (APIs) from key sourcing regions?
- What are the potential ripple effects of tariffs on finished drug product pricing and availability?
- Which geographical trade routes are most exposed to existing or proposed tariff measures?
- How are pharmaceutical companies adjusting their supply chain strategies in response to tariff risks?
Signals to watch
- Announcements of new trade policies or tariff proposals affecting pharmaceutical components.
- Changes in import/export data for pharmaceutical raw materials.
- Public statements from industry associations regarding trade barriers.
- Shifts in manufacturing or sourcing locations by major pharmaceutical companies.
Decisions it supports
- Supply chain diversification and resilience strategies.
- Sourcing decisions for active pharmaceutical ingredients and excipients.
- Manufacturing footprint optimization and relocation assessments.
- Pricing adjustments and market access strategies in affected regions.
How it is built
Prepared after your order from dated public sources - such as pharma & biotech filings and announcements, regulatory records, trials, patents and trade data, where relevant - and our market model. Reported facts are cited, estimates are labelled and our assessment is marked as such, following our research method. You receive our verdict, the evidence, who is exposed, the signals to watch and recommended actions, within 24 hours.
Questions
What are pharmaceutical tariffs?
Pharmaceutical tariffs are taxes or duties imposed on imported pharmaceutical products, raw materials, or components. These can be levied by governments to protect domestic industries, generate revenue, or as a tool in broader trade negotiations. They directly increase the cost of goods crossing international borders within the pharmaceutical supply chain.
How do tariffs impact drug supply chains?
Tariffs can disrupt drug supply chains by increasing the cost of imported ingredients, making certain manufacturing locations less competitive, and potentially leading to shortages if suppliers cannot absorb the added expenses. This can force companies to seek new suppliers, redesign products, or pass increased costs onto consumers, affecting drug affordability and availability.
What can companies do to mitigate tariff exposure?
To mitigate tariff exposure, companies can diversify their sourcing of raw materials and manufacturing locations, reducing reliance on single countries or trade routes. They might also explore reshoring or nearshoring production, invest in domestic manufacturing capabilities, or engage in strategic inventory management to buffer against potential disruptions and cost increases.